Enemaxal® (Solvent) Instructions for Use
Marketing Authorization Holder
Kirov Pharmaceutical Factory, JSC (Russia)
ATC Code
A06AG01 (Sodium phosphate)
Active Substances
Sodium hydrogen phosphate (Group)
Sodium dihydrogen phosphate (BP)
Dosage Form
| Enemaxal® | Rectal solution 0.08 g+0.181 g/1 ml: bottle-enema 120 ml |
Dosage Form, Packaging, and Composition
Rectal solution transparent, colorless.
| 1 ml | |
| Sodium phosphate dibasic dodecahydrate | 0.08 g |
| Sodium phosphate monobasic dihydrate | 0.181 g |
Excipients : sodium benzoate – 0.004 g, phosphoric acid – to pH 5.0-5.8, water – to 1 ml.
120 ml – single-use bottle-enemas* (1) – cardboard packs.
* with or without a rectal applicator.
Clinical-Pharmacological Group
Laxative drug with osmotic properties
Pharmacotherapeutic Group
Laxative
Pharmacological Action
Saline laxative.
The action is based on increasing the retention of fluid in the intestine through osmotic processes.
The accumulation of fluid in the intestine leads to increased peristalsis and subsequent bowel emptying.
The effect develops within 5-7 minutes after administration.
Pharmacokinetics
Sodium phosphate is poorly absorbed in the intestine; however, absorption of sodium and phosphate ions does occur and is dose-dependent.
Indications
Constipation; preparation for endoscopic examination of the rectum; preparation for X-ray examination of the abdominal organs; preparation for surgical operations on the abdominal organs, childbirth.
ICD codes
| ICD-10 code | Indication |
| K59.0 | Constipation |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| DB32.1 | Slow-transit constipation |
| DD91.1 | Functional constipation |
| DE2Z | Diseases of the digestive system, unspecified |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer Enemaxal®rectally using the provided single-use bottle-enema.
For constipation in adults, use the entire 120 ml contents of one bottle-enema as a single dose.
For pre-procedural bowel cleansing prior to endoscopic or X-ray examination, surgery, or childbirth, use the entire 120 ml contents of one bottle-enema as directed by a physician.
Do not use orally. The rectal solution is for rectal use only.
Ensure the patient is positioned comfortably, typically lying on their left side with knees bent.
Gently insert the rectal applicator tip into the anus and slowly squeeze the bottle to empty the entire contents into the rectum.
Dispose of the used bottle-enema after a single application; do not reuse.
The laxative effect typically develops within 5 to 7 minutes after administration.
This product is contraindicated in patients under 18 years of age.
Maintain adequate fluid intake during use. Monitor electrolyte levels before and after use, especially in at-risk patients.
Adverse Reactions
Possible allergic reactions, nausea, vomiting, abdominal pain, local irritant effect (irritation around the anus).
Contraindications
Intestinal obstruction, intestinal perforation, acute inflammatory and/or ulcerative lesions of the distal intestines, acute hemorrhoids, anal fissures, age under 18 years, hypersensitivity to the active substances.
Use in Pregnancy and Lactation
Use is possible for preparation for childbirth according to indications when the potential benefit outweighs the risk of use. Use during breastfeeding is not recommended.
Use in Renal Impairment
The drug is contraindicated for use in renal impairment.
Pediatric Use
The drug is contraindicated for use in children and adolescents under 18 years of age.
Special Precautions
When using this product, patients should maintain adequate fluid intake.
Electrolyte levels should be monitored before and after use.
If no bowel movement occurs within 6 hours after oral administration, the patient should be asked to stop taking this product and consult a doctor, as dehydration may develop.
Drug Interactions
When used rectally, consultation with a doctor is necessary if the patient is taking anticoagulants, digitalis preparations, ciprofloxacin, etidronate, sodium polystyrene sulfonate, or tetracycline antibiotics.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
OKI, sachets 80mg 2g, 12pcs
Belosalic, lotion solution for external use spray 100ml
Noopept, pills 10mg, 50pcs
Kagocel pills 12mg, 30pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Ingavirin capsules 90mg, 10pcs
Fenotropil pills 100mg, 60pcs
No-spa pills 40mg, 64pcs
Actovegin pills 200mg, 50pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Daivobet, ointment, 30g
Phenibut-Vertex pills 250mg, 20pcs
Cortexin, 10mg, 5ml, 10pcs
Picamilon pills 50mg, 60pcs
Belosalic, ointment, 30g
Nootropil pills 800mg, 30pcs 